Axon Enterprise, Inc. filings document operating results and corporate actions for a public safety technology company with Software & Services and Connected Devices activities. Form 8-K reports include shareholder letters on financial results and outlooks, product demand across TASER devices, Axon Body cameras, Axon Evidence, AI products, counter-drone offerings and real-time operations, as well as material-event disclosures tied to capital structure.
Proxy materials cover board composition, shareholder meeting matters, executive compensation and equity awards. Other 8-K and 8-K/A filings record director election updates and the redemption and settlement of 0.50% convertible senior notes due 2027, including the disclosure that no convertible notes remained outstanding after the redemptions and conversions.
AXON ENTERPRISE, INC. reported that Chief Accounting Officer Jennifer H. Mak acquired 3,906 shares of common stock through settlement of performance-based restricted stock units (XSUs). These XSUs were granted on December 22, 2023 under the 2024 eXponential Stock Plan, with performance for the fourth tranche certified as achieved on August 16, 2026. The tranche is scheduled to vest on December 1, 2026, subject to continued employment, and the delivered shares will be subject to a minimum holding period. Following this award, Mak directly holds 13,755.968 shares of Axon common stock.
AXON ENTERPRISE, INC. reported that officer Elizabeth Reid Coughlin, Chief Human Officer, acquired 6,818 shares of common stock in the form of performance-based restricted stock units (XSUs). These units relate to a grant made on December 22, 2023, for which the fourth tranche’s performance conditions were certified as achieved on August 16, 2026. The tranche is scheduled to vest on December 1, 2026, subject to continued employment, and the shares will be subject to a minimum holding period extending to the earlier of December 31, 2030 or the vesting of a subsequent tranche. Following this acquisition, Coughlin holds 40,841.833 shares of Axon common stock directly.
AXON ENTERPRISE, INC. reported that Chief Legal Officer Isaiah Fields acquired 10,488 shares of common stock via vesting of performance-based restricted stock units (XSUs). These units were originally granted on December 22, 2023 under the 2024 eXponential Stock Plan after the Compensation Committee certified performance for the fourth tranche on August 16, 2026.
The tranche is scheduled to vest on December 1, 2026, subject to continued employment, and the resulting shares are subject to a minimum holding period until the earlier of December 31, 2030 or a subsequent tranche vesting, excluding any shares withheld or sold for taxes. Following this award, Fields directly holds 58,044.014 shares of Axon common stock.
AXON ENTERPRISE, INC. reported that Chief Revenue Officer Cameron Brooks acquired 15,810 shares of common stock through the certification of performance-based restricted stock units (XSUs) under the 2024 eXponential Stock Plan. These units relate to the fourth tranche, whose performance conditions were certified as met on August 16, 2026. The tranche is scheduled to vest on April 1, 2027, subject to continued employment, and the resulting shares will be subject to a minimum holding period until the earlier of December 31, 2030 or the vesting of a subsequent tranche, excluding any shares withheld or sold for taxes. Following this award, Brooks holds 67,980.933 shares of Axon common stock directly.
AXON ENTERPRISE, INC. reported that CEO and director Patrick W. Smith acquired 97,015 shares of Common Stock through performance-based restricted stock units tied to the fourth tranche of the 2024 CEO Performance Award. The Compensation Committee certified the performance conditions on August 16, 2026, resulting in this grant. Following the award, Smith directly holds 3,128,012 shares. These units will vest on December 31, 2029, subject to continued employment, and vested shares are subject to a minimum holding period extending until the earlier of December 31, 2030 or the vesting of a subsequent tranche, excluding any shares withheld for taxes.
Axon Enterprise, Inc., acting as an institutional investment manager, filed a Form 13F holdings report indicating that it manages one reportable position under the 13F reporting rules. The aggregate market value of this position is $19,126,190, based on the required reporting methodology.
The report lists no other included managers, meaning Axon Enterprise, Inc. is the sole reporting manager for these holdings in this filing.
Axon Enterprise, Inc. director and chief executive officer Patrick W. Smith reported a sale of 70 shares of common stock on August 7, 2026 at a weighted average price of $566.6186 per share, executed under a Rule 10b5-1 trading plan adopted on May 12, 2025. Following this transaction, he held 3,030,997 shares of Axon common stock directly.
AXON ENTERPRISE, INC. chief executive officer Patrick W. Smith reported open-market sales of a total of 9,930 shares of common stock on August 7, 2026. The 30 transactions were executed at per-share prices ranging from $526.5195 to $565.6468 pursuant to a pre-established Rule 10b5-1 trading plan adopted on May 12, 2025.
Axon Enterprise, Inc. insider trading plan: An affiliate of Patrick W. Smith has filed to sell 10,000 shares of Axon common stock through UBS Financial Services on or about August 7, 2026, on Nasdaq, with an aggregate market value of $5,263,200.00. The filing also lists prior sales by Smith over the past three months totaling 40,000 shares for combined proceeds exceeding $21.4 million.
Isner Joshua reported acquisition or exercise transactions in this Form 4 filing.
Axon Enterprise, Inc. reported that its president, Joshua Isner, received a grant of 78,200 service-based restricted stock units of common stock on 2026-08-05 under the Amended and Restated 2022 Stock Incentive Plan. The units vest in 12 equal quarterly installments from November 13, 2026 through August 13, 2029, leaving him with 247,324.629 shares directly owned after the grant.